Nascent Pharma Holdings, Inc.
NASC
$0.02
$0.00-8.33%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -96.35% | -35.26% | -60.70% | -43.42% | -85.49% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -96.35% | -35.26% | -60.70% | -43.42% | -85.49% |
| Cost of Revenue | -66.35% | -28.78% | 127.45% | -209.36% | 20.05% |
| Gross Profit | 50.96% | 23.47% | -298.72% | 923.85% | -143.93% |
| SG&A Expenses | -11.92% | -10.25% | -13.88% | 32.46% | -68.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -25.70% | -- |
| Total Operating Expenses | -28.75% | -17.97% | 17.35% | -68.41% | -58.86% |
| Operating Income | 20.83% | 13.98% | -68.44% | 74.83% | 47.60% |
| Income Before Tax | 21.67% | -0.08% | -256.26% | 37.69% | 39.58% |
| Income Tax Expenses | -- | -- | -- | -100.00% | -- |
| Earnings from Continuing Operations | 21.67% | -0.08% | -254.30% | 37.71% | 39.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 21.67% | -0.08% | -254.30% | 37.71% | 39.58% |
| EBIT | 20.83% | 13.98% | -68.44% | 74.83% | 47.60% |
| EBITDA | 12.21% | -4.41% | -93.78% | 86.53% | 50.19% |
| EPS Basic | 86.12% | 89.84% | 53.55% | 90.88% | 81.81% |
| Normalized Basic EPS | 86.11% | 89.83% | 77.84% | 90.87% | 81.81% |
| EPS Diluted | 86.12% | 89.19% | 53.55% | 90.88% | 81.81% |
| Normalized Diluted EPS | 86.11% | 89.83% | 77.84% | 90.87% | 81.81% |
| Average Basic Shares Outstanding | 464.59% | 883.77% | 662.52% | 582.49% | 232.19% |
| Average Diluted Shares Outstanding | 464.59% | 883.77% | 662.52% | 582.49% | 232.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |